H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Tuesday, setting a price target of $66, which is approximately 43.10% above the present share price of $46.12.
Bernardino expects Cassava Sciences to post earnings per share (EPS) of -$0.06 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Cassava Sciences, with an average price target of $34.67.
The analysts price targets range from a high of $66 to a low of $14.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$1.44 million. The company's market cap is $1.61 billion.
According to TipRanks.com, H.C. Wainwright analyst Vernon Bernardino is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 43.2% and a 43.22% success rate.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.